TABLE 3.
Overall median survival of patients and the factors that could potentially have an impact on survival
| Survival, months
|
|||
|---|---|---|---|
| Factor | Median | 95% CI | P |
| Age at diagnosis, years | |||
| ≤70 | 14.8 | 11.8 to 20.5 | 0.388 |
| > 70 | 13.6 | 11.3 to 16.6 | |
| Sex | |||
| Female | 11.8 | 8.3 to 15.7 | 0.038 |
| Male | 14.8 | 13.1 to 19.2 | |
| Disease site | |||
| Cardia/lower | 14.8 | 13.1 to 19.2 | 0.080 |
| Middle/upper | 10.9 | 8.4 to 16.6 | |
| Histology | |||
| Adenocarcinoma/other | 13.9 | 11.8 to 19.1 | 0.613 |
| Squamous | 14.4 | 11.3 to 17.3 | |
| T stage | |||
| TX/T1/T2 | 13.2 | 10.9 to 16.4 | 0.076 |
| T3 | 17.3 | 13.8 to NE* | |
| Nodal involvement | |||
| Yes | 15.1 | 11.8 to 19.2 | 0.600 |
| No | 13.3 | 10.8 to 19.1 | |
| Unknown | 13.6 | 10.9 to 22.4 | |
| Treatment regimens | |||
| RT only | 11.8 | 10.3 to 13.6 | <0.0001 |
| All others | 23.5 | 14.8 to 84.6 | |
| RT only | 11.8 | 10.3 to 13.6 | |
| RT + RS | 24.9† | 14.8 to NE* | |
| RT + ChT | 14.5 | 8.9 to NE* | |
| RT + ChT + RS | 33.3 | 20.5 to NE* | |
| Number of treatment modalities | |||
| 1 | 11.8 | 10.3 to 13.6 | |
| 2 | 19.2 | 14.3 to 35.1 | |
| 3 | 33.3 | 20.5 to NE* | |
| Diagnosis year | |||
| 1995 to 1999 | 13.9 | 11.8 to 16.6 | 0.447 |
| 2000 to 2003 | 14.6 | 11.1 to 23.5 | |
| Type of RT (RT only group) | |||
| External only | 14.8 | 11.8 to 18.8 | 0.942 |
| External + endoluminal brachytherapy | 13.6 | 11.1 to 19.1 | |
| Total dose of external RT | |||
| < 50 Gy | 13.3 | 10.7 to 16.4 | 0.119 |
| ≥50 Gy | 15.1 | 12.1 to 24.2 | |
P<0.05 was defined as significant.
*
Not estimable (NE) (ie, the upper limit of the 95% CI for the median survival was not reached);
†
Because the number of patients in the subgroup treated with surgery followed by radiation therapy (RT) was very small (n=7), for the purpose of the analysis, it was combined with the subgroup treated with RT followed by surgery (n=16). ChT Chemotherapy; RS Radical surgery